Etoricoxib
ARBIX
Regulatory Class: Rx
Generic Name: Etoricoxib
Formulation/s: 120 mg Film-Coated Tablet
Indications or Use: Signs & symptoms of acute Osteoarthritis & Rheumatoid Arthritis. Management of acute pain associated w/ inflammation.
Dosage and Directions for Use: For Osteoarthritis take 30 mg once daily, increased to 120 mg once daily if necessary. For Rheumatoid Arthritis 90 mg once daily. For Acute gouty arthritis 120 mg once daily, max of 8 days.
Administration: Take with or without food.
Contraindication: Not to be given to patients who have history of Stroke; Myocardial Infarction; Coronary Artery Bypass Graft ; uncontrolled Hypertension; Coronary Heart Failure NYHA II-IV.
Special Precaution: Not to be given to patients w/ allergy to NSAIDs & Asthma. Patients w/ ischemic heart disease, risk factors for heart disease, HTN, hyperlipidemia, diabetes, smoking & peripheral arterial disease. Use the lowest effective dose for the shortest duration of treatment in patients w/ CV risk. Discontinue use if appearance of skin rash & signs of hypersensitivity occurs. Potential GI (gastric & liver) & renal toxicities. Not to be used in patients w/ HTN whose BP is inadequately controlled. Contraindicated in patients w/ inflammatory bowel disease, moderate to severe heart failure & renal impairment (CrCl <30 mL/min). May affect ability to drive & use machines. Not recommended in women attempting to conceive. Contraindicated in pregnancy. Lactation.
Adverse Reaction: GI discomfort, nausea, & diarrhea; peptic ulceration & severe GI bleeding. Headache, vertigo, dizziness, nervousness, tinnitus, depression, drowsiness, & insomnia. Fever, angioedema, bronchospasm, & rashes. Hepatotoxicity & aseptic meningitis. Visual disturbance. Anemia, thrombocytopenia, neutropenia, eosinophilia, & agranulocytosis. Interstitial nephritis & nephrotic syndrome; renal failure. Hematuria. Nephropathy. Fluid retention. Photosensitivity, alveolitis, pulmonary eosinophilia, pancreatitis, SJS & TENs. Induction or exacerbation of colitis.
Interactions: Changes in plasma concentration w/ drugs that inhibit or induce CYP450 isoenzyme CYP3A4. Decreased plasma concentration w/ Rifampicin. Increased plasma concentration of Ethinylestradiol. Oral Salbutamol & Minoxidil.
Presentation/ Packaging: Film-coated Tablet 120 mg. x 100’s.
For more information, please see full product information.
